Total Payments
$9,683
2024 Payments
$322.70
Companies
45
Transactions
552
Medicare Patients
10,357
Medicare Billing
$2.6M
Payment Breakdown by Category
Food & Beverage$9,538 (98.5%)
Education$91.02 (0.9%)
Consulting$54.22 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $9,538 | 547 | 98.5% |
| Education | $91.02 | 2 | 0.9% |
| Consulting Fee | $54.22 | 3 | 0.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $1,664 | 95 | $0 (2024) |
| ABBVIE INC. | $1,285 | 72 | $0 (2024) |
| NESTLE HEALTHCARE NUTRITION INC. | $1,188 | 54 | $0 (2023) |
| Valeant Pharmaceuticals North America LLC | $650.99 | 22 | $0 (2017) |
| Novo Nordisk Inc | $572.73 | 34 | $0 (2024) |
| Ferring Pharmaceuticals Inc. | $480.29 | 25 | $0 (2023) |
| Merck Sharp & Dohme Corporation | $391.71 | 34 | $0 (2021) |
| Takeda Pharmaceuticals U.S.A., Inc. | $359.19 | 25 | $0 (2020) |
| Amarin Pharma Inc. | $252.69 | 19 | $0 (2022) |
| Daiichi Sankyo Inc. | $231.83 | 13 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $322.70 | 17 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($119.58) |
| 2023 | $772.46 | 38 | AstraZeneca Pharmaceuticals LP ($154.39) |
| 2022 | $1,209 | 67 | Nestle HealthCare Nutrition Inc. ($358.53) |
| 2021 | $1,514 | 80 | Nestle HealthCare Nutrition Inc. ($717.89) |
| 2020 | $747.24 | 42 | AbbVie Inc. ($144.77) |
| 2019 | $1,888 | 120 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($542.52) |
| 2018 | $1,308 | 85 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($251.87) |
| 2017 | $1,922 | 103 | Valeant Pharmaceuticals North America LLC ($650.99) |
All Payment Transactions
552 individual payment records from CMS Open Payments — Page 1 of 23
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/26/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $24.74 | General |
| Category: PSYCHIATRY | ||||||
| 11/20/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $20.75 | General |
| Category: Gastroenterology | ||||||
| 11/05/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $18.31 | General |
| 09/11/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $18.48 | General |
| Category: Gastroenterology | ||||||
| 08/13/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $20.84 | General |
| Category: PSYCHIATRY | ||||||
| 08/08/2024 | ABBVIE INC. | VIBERZI (Drug), CREON | Food and Beverage | In-kind items and services | $23.18 | General |
| Category: GASTROENTEROLOGY | ||||||
| 07/16/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $16.20 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 06/10/2024 | Lilly USA, LLC | JARDIANCE (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $19.33 | General |
| Category: Diabetes | ||||||
| 06/06/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $19.07 | General |
| Category: Gastroenterology | ||||||
| 05/28/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $16.94 | General |
| Category: Respiratory | ||||||
| 05/16/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $13.93 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 05/01/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $20.32 | General |
| Category: Gastroenterology | ||||||
| 03/20/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $21.42 | General |
| Category: Gastroenterology | ||||||
| 03/19/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $16.65 | General |
| 02/29/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $14.95 | General |
| Category: GASTROENTEROLOGY | ||||||
| 02/27/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $18.05 | General |
| Category: Respiratory | ||||||
| 02/14/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $19.54 | General |
| Category: Gastroenterology | ||||||
| 12/20/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $10.50 | General |
| Category: Gastroenterology | ||||||
| 11/28/2023 | AbbVie Inc. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $21.58 | General |
| Category: VIROLOGY | ||||||
| 11/01/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $21.89 | General |
| Category: Gastroenterology | ||||||
| 10/10/2023 | NESTLE HEALTHCARE NUTRITION INC. | VOWST (Biological) | Food and Beverage | In-kind items and services | $21.16 | General |
| Category: GI | ||||||
| 09/20/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: Gastroenterology | ||||||
| 09/19/2023 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $19.11 | General |
| Category: Neuroscience | ||||||
| 09/12/2023 | AbbVie Inc. | VIBERZI (Drug), LINZESS | Food and Beverage | In-kind items and services | $16.57 | General |
| Category: GASTROENTEROLOGY | ||||||
| 08/23/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $15.94 | General |
| Category: Gastroenterology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 18 | 1,894 | 10,263 | $1.9M | $855,206 |
| 2022 | 19 | 2,173 | 10,107 | $1.8M | $728,919 |
| 2021 | 20 | 1,909 | 7,933 | $1.3M | $561,828 |
| 2020 | 51 | 4,381 | 9,534 | $1.1M | $424,002 |
Total Patients
10,357
Total Services
37,837
Medicare Billing
$2.6M
Procedure Codes
108
All Medicare Procedures & Services
108 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99309 | Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | Facility | 2023 | 294 | 3,467 | $658,730 | $336,063 | 51.0% |
| 99308 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | Facility | 2023 | 307 | 4,847 | $848,225 | $330,868 | 39.0% |
| 99306 | Initial nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | Facility | 2023 | 248 | 302 | $75,500 | $49,869 | 66.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 104 | 282 | $67,125 | $39,755 | 59.2% |
| 99316 | Nursing facility discharge management, more than 30 minutes | Facility | 2023 | 241 | 286 | $71,500 | $34,266 | 47.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 120 | 316 | $66,650 | $30,635 | 46.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 89 | 138 | $21,470 | $9,164 | 42.7% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 63 | 63 | $12,600 | $8,916 | 70.8% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 52 | 53 | $6,625 | $4,001 | 60.4% |
| 99497 | Advance care planning, first 30 minutes | Office | 2023 | 49 | 50 | $10,000 | $3,485 | 34.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 120 | 240 | $3,600 | $2,016 | 56.0% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 55 | 56 | $2,240 | $2,015 | 90.0% |
| G0181 | Physician or allowed practitioner supervision of a patient receiving medicare-covered services provided by a participating home health agency (patient not present) requiring complex and multidisciplinary care modalities involving regular physician or allow | Office | 2023 | 16 | 16 | $2,400 | $1,359 | 56.6% |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2023 | 32 | 35 | $4,375 | $1,212 | 27.7% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 29 | 30 | $1,500 | $603.99 | 40.3% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 47 | 52 | $3,380 | $573.32 | 17.0% |
| G0446 | Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes | Office | 2023 | 12 | 12 | $600.00 | $343.32 | 57.2% |
| 81002 | Urinalysis, manual test | Office | 2023 | 16 | 18 | $270.00 | $61.38 | 22.7% |
| 99308 | Follow-up nursing facility visit per day, typically 15 minutes | Facility | 2022 | 389 | 5,744 | $1.0M | $369,147 | 36.7% |
| 99309 | Follow-up nursing facility visit per day, typically 25 minutes | Facility | 2022 | 259 | 2,039 | $387,395 | $171,090 | 44.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 174 | 481 | $96,200 | $45,767 | 47.6% |
| 99306 | Initial nursing facility visit per day, typically 45 minutes | Facility | 2022 | 225 | 249 | $62,250 | $37,875 | 60.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 103 | 202 | $45,450 | $32,356 | 71.2% |
| 99316 | Nursing facility discharge management, more than 30 minutes | Facility | 2022 | 197 | 221 | $55,150 | $21,025 | 38.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 128 | 262 | $34,350 | $18,559 | 54.0% |
About Dr. Jay Stambler, M.D
Dr. Jay Stambler, M.D is a Internal Medicine healthcare provider based in East Islip, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1821029026.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jay Stambler, M.D has received a total of $9,683 in payments from pharmaceutical and medical device companies, with $322.70 received in 2024. These payments were reported across 552 transactions from 45 companies. The most common payment nature is "Food and Beverage" ($9,538).
As a Medicare-enrolled provider, Stambler has provided services to 10,357 Medicare beneficiaries, totaling 37,837 services with total Medicare billing of $2.6M. Data is available for 4 years (2020–2023), covering 108 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Gastroenterology
- Location East Islip, NY
- Active Since 07/05/2006
- Last Updated 04/10/2008
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1821029026
Products in Payments
- XIFAXAN (Drug) $2,226
- ZENPEP (Drug) $1,167
- Amitiza (Drug) $291.48
- Mavyret (Drug) $284.47
- LINZESS (Drug) $283.97
- Humira (Biological) $267.30
- Vascepa (Drug) $252.69
- INJECTAFER (Drug) $231.83
- CLENPIQ (Drug) $193.92
- MAVYRET (Drug) $172.07
- LOKELMA (Drug) $154.39
- Ozempic (Drug) $145.17
- XELJANZ (Drug) $141.98
- Victoza (Drug) $135.24
- CIMZIA (Drug) $134.38
- OCALIVA (Drug) $132.79
- VIBERZI (Drug) $129.01
- JANUVIA (Drug) $125.96
- PREPOPIK (Drug) $111.63
- EMGALITY (Drug) $98.45
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.